Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR) is a specialized subtype of pentameric ligand-gated ion channel primarily localized within the catecholaminergic nuclei of the brain, including the substantia nigra and ventral tegmental area (UniProt Consortium, 2024, 'CHRNA6 - Neuronal acetylcholine receptor subunit alpha-6'). These receptors play a pivotal role in the presynaptic regulation of dopamine release in the striatum, making them essential components of the neural circuits governing motor control and reward processing (Quik et al., 2011, 'Alpha6-containing nicotinic receptors: a target for Parkinson's disease?'). The asterisk in its nomenclature indicates that these receptors often co-assemble with other subunits, such as the beta-3 or alpha-4 subunits, to form functional complexes. Due to their restricted expression pattern, α6β2* receptors are considered high-priority therapeutic targets for Parkinson's disease, as their selective loss is a hallmark of dopaminergic neurodegeneration. Furthermore, they are heavily implicated in the reinforcing properties of nicotine, suggesting that selective ligands could provide more effective treatments for nicotine addiction with fewer side effects than non-selective agonists (PubMed, 2023, 'Targeting alpha6-containing nicotinic receptors for tobacco cessation'). Pharmacological strategies currently focus on developing potent partial agonists or antagonists that can modulate dopamine levels without triggering the widespread off-target effects associated with broader nicotinic receptor activation.
The receptor acts as a pentameric ligand-gated ion channel that, upon binding of acetylcholine or nicotine, undergoes a conformational change to open a cation-selective pore, leading to depolarization and the modulation of neurotransmitter release, particularly dopamine in the striatum (Gotti et al., 2010, 'Nicotinic acetylcholine receptors: a complex family of ligand-gated ion channels with different roles in the CNS').
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-6 beta-2 nicotinic acetylcholine receptor (α6β2* nAChR).